

Special Issue

Human Cytomegalovirus Therapeutic Strategies and Clinical Applications

Message from the Guest Editor

Human cytomegalovirus (HCMV) is the most common congenital infection worldwide and significantly impacts morbidity, mortality, and cost of care after transplantation. It affects pregnancies, child health, and transplant outcomes. Despite its critical impact on human health, treatment options for HCMV are limited. The nucleoside analog ganciclovir (GCV) and its oral formulation val-GCV improved transplant outcomes, val-GCV may prevent hearing deterioration in congenitally infected children. However, long-term use can lead to severe bone marrow toxicity and resistance. Alternative drugs for GCV-resistant HCMV, foscarnet, and cidofovir, also target viral DNA polymerase; both are nephrotoxic and require intravenous administration. New agents like the terminase inhibitor letermovir and the UL97 kinase inhibitor maribavir have been approved for specific HCMV cases. Given the emergence of resistance to all agents, there's a great need for additional treatment options for HCMV, including new therapeutic strategies. The Special Issue will focus on recent advances in HCMV therapeutic strategies and specific treatment considerations for patients at risk for CMV disease.

Guest Editor

Dr. Ravit Arav-Boger

Department of Pediatrics, Division of Infectious Disease, Medical
College of Wisconsin, Milwaukee, WI 53226, USA

Deadline for manuscript submissions

30 April 2025



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



mdpi.com/si/220905

Viruses
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 7.3
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Editor-in-Chief

Dr. Eric O. Freed

Director, HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2024).